Edition:
India

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

10.26EUR
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
€10.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
351,049
52-wk High
€13.68
52-wk Low
€7.65

Chart for

About

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.... (more)

Overall

Beta: 0.53
Market Cap(Mil.): €275.62
Shares Outstanding(Mil.): 29.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%

03 Nov 2017

BRIEF-‍Nicox enters research collaboration with Re-Vana Therapeutics

* ‍Nicox enters research collaboration with Re-Vana Therapeutics on its next generation of stand-alone no-donors in a novel sustained release ophthalmic formulation​

20 Oct 2017

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

10 Oct 2017

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

10 Oct 2017

BRIEF-Nicox announces licensing agreement with Eyevance

* ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES

21 Sep 2017

BRIEF-Nicox H1 operating loss narrows to ‍​11.6 million euros

* ‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​

08 Sep 2017

BRIEF-NicOx raises $31 million in private placement of shares

* ANNOUNCED ON THURSDAY A PRIVATE PLACEMENT OF SHARES TO RAISE EUR 26.25 MILLION (USD 30.97 MILLION)

18 Aug 2017

BRIEF-Nicox lists 3.5 million new shares on Euronext Paris

* NICOX SA TO LIST 3.5 MILLION NEW SHARES ON EURONEXT PARIS AS OF AUGUST 17; REFERENCE PRICE: EUR 7.5 Further company coverage: (Gdynia Newsroom)

16 Aug 2017

BRIEF-Nicox announces 26.25 million euros financing

* NICOX SA - ‍RESERVED CAPITAL INCREASE OF ORDINARY SHARES OF COMPANY TO A SPECIFIC CATEGORY OF INVESTORS​

15 Aug 2017

Earnings vs. Estimates